Beyond Bulls & Bears

Biotech Innovations Remain at Forefront
Equity

Biotech Innovations Remain at Forefront

The first quarter of 2021 was challenging for investors in biotechnology, but Franklin Equity Group Portfolio Managers Evan McCulloch, Wendy Lam and Akiva Felt believe the second half of the year will likely bring welcome tailwinds for the industry. They offer an update on investment opportunities they see, and why they believe biotech companies will remain at the forefront through the pandemic period and beyond.

Quick Thoughts: Biotech Progress in Addressing Coronavirus, but It Takes Time
Equity

Quick Thoughts: Biotech Progress in Addressing Coronavirus, but It Takes Time

With the coronavirus creating havoc across the globe, researchers are rushing to find better treatment options and a cure. Our Head of Equities, Stephen Dover, and Portfolio Manager Evan McCulloch outline a few of the efforts the medical and scientific communities are taking to combat the virus.

PODCAST: Health Care Sector Innovation and Insight
Equity

PODCAST: Health Care Sector Innovation and Insight

The biopharma industry has the potential to save lives with dramatic breakthroughs in new therapeutic drugs. In our latest “Talking Markets” podcast, our Head of Equities Stephen Dover speaks with analysts Steven Kornfeld and Krzysztof Musialik about health care innovations, particularly in the area of biopharma. They point out that in some cases, emerging markets are actually leading the way.

3 Reasons Why Investors Should Ignore Political Threats to Biotech
Equity

3 Reasons Why Investors Should Ignore Political Threats to Biotech

Given that the United States is considered a world leader in pharmaceutical innovation, we think it’s unlikely that politicians would want to impede the profit motivation of innovation and potentially severely impair the industry’s growth.